Volume 63, Issue 4, Pages (April 2003)

Slides:



Advertisements
Similar presentations
The Clinical Guide “A Guide to Implementing Renal Best Practice in Haemodialysis“ Chapter 5: Anticoagulation Team Leader: Angela Henson Co-authors: Franta.
Advertisements

Anticoagulants 1. Parenteral Anticoagulants e.g. heparin
Fibrinolytics, anticoagulants and antiplatelets
Systemic anticoagulation during ECMO is intended to control thrombin generation and limit the risk for thrombotic and hemorrhagic complications.
ANTICOAGULATION IN HAEMODIALYSIS
Consultant nephrologist Shirbin General Hospital
ANTICUAGULANT A.Rahimzadeh.B.sc,M.sc Shahid Beheshty university
Volume 63, Issue 4, Pages (April 2003)
Increased cGMP phosphodiesterase activity mediates renal resistance to ANP in rats with bile duct ligation  Xi-Ping Ni, Massy Safai, David G. Gardner,
Antibodies to Heparin–Platelet Factor 4 Complex: Pathogenesis, Epidemiology, and Management of Heparin-Induced Thrombocytopenia in Hemodialysis  Andrew.
Selenium-deficient diet induces renal oxidative stress and injury via TGF-β1 in normal and diabetic rats  Alluru S. Reddi, Jaya S. Bollineni  Kidney International 
E. Cavalier, P. Delanaye, A. Carlisi, J. -M. Krzesinski, J. -P
Heparinless cardiopulmonary bypass with active-site blocked factor IXa: A preliminary study on the dog  Talia B. Spanier, MDa, Mehmet C. Oz, MDa, Oktavijan.
by Nadine Martel, James Lee, and Philip S. Wells
How to Interpret and Pursue an Abnormal Prothrombin Time, Activated Partial Thromboplastin Time, and Bleeding Time in Adults  Arif H. Kamal, MD, Ayalew.
Renal hemodynamics in radiocontrast medium-induced renal dysfunction: A role for dopamine-1 receptors  George L. Bakris, M.D, Nancy A. Lass, Dana Glock 
End-stage renal disease in developing countries
Volume 58, Issue 4, Pages (October 2000)
Stem cells for kidney repair: useful tool for acute renal failure?
Recombinant activated factor VII and prothrombin complex concentrates have different effects on bleeding and arterial thrombosis in the haemodiluted rabbit 
Summary of Recommendation Statements
Volume 55, Issue 2, Pages (February 1999)
Volume 65, Issue 2, Pages (February 2004)
New oral anticoagulants—what the cardiothoracic surgeon needs to know
Antibodies to Heparin–Platelet Factor 4 Complex: Pathogenesis, Epidemiology, and Management of Heparin-Induced Thrombocytopenia in Hemodialysis  Andrew.
Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients  Demetrios J. Kutsogiannis, R.T.Noel.
Ganesan Ramesh, W. Brian Reeves  Kidney International 
Evidence Supporting Idarucizumab for the Reversal of Dabigatran
Heparin-coated dialyzer membranes: is non-inferiority good enough?
Volume 61, Issue 4, Pages (April 2002)
Volume 62, Issue 2, Pages (August 2002)
Section 5: Dialysis Interventions for Treatment of AKI
Pharmacokinetics of low-molecular-weight heparin and unfractionated heparin during elective aortobifemoral bypass grafting  Herman Kroneman, MD, Bert.
Volume 55, Issue 2, Pages (February 1999)
Prediction of hypertension in chronic hemodialysis patients
Comorbidity and confounding in end-stage renal disease
Volume 70, Issue 2, Pages (July 2006)
The identification and management of heparin-induced thrombocytopenia in the vascular patient  Glenn M. LaMuraglia, MD, Rabih Houbballah, MD, Michael.
N-terminal fragments of the proatrial natriuretic peptide in patients before and after hemodialysis treatment  Martina Franz, Wolfgang Woloszczuk, Walter.
Volume 70, Issue 11, Pages (December 2006)
Body weight is a fluctuating parameter in hemodialysis patients
Volume 60, Issue 6, Pages (December 2001)
Volume 60, Issue 1, Pages (July 2001)
Volume 66, Issue 1, Pages (July 2004)
Gentamicin pharmacokinetics during slow daily home hemodialysis
Volume 78, Issue 8, Pages (October 2010)
John H. Wiessner, Linda Y. Hung, Neil S. Mandel  Kidney International 
Extracorporeal therapy in sepsis: are we there yet?
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
Volume 57, Issue 5, Pages (May 2000)
Volume 53, Issue 4, Pages (April 1998)
Increased cGMP phosphodiesterase activity mediates renal resistance to ANP in rats with bile duct ligation  Xi-Ping Ni, Massy Safai, David G. Gardner,
Circadian regulation of renal function
Volume 57, Issue 6, Pages (June 2000)
Ganesan Ramesh, W. Brian Reeves  Kidney International 
Volume 73, Issue 9, Pages (May 2008)
Hemodialysis and L-arginine, but not D-arginine, correct renal failure-associated endothelial dysfunction  Malcolm F. Hand, William G. Haynes, David J.
Volume 59, Issue 1, Pages (January 2001)
Strategies for iron supplementation: Oral versus intravenous
Volume 62, Issue 5, Pages (November 2002)
Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis  Karl-Georg Fischer, M.D., Andreas van.
Rebound kinetics of β2-microglobulin after hemodialysis
Taqumpay Esmiraldo Tigcal Sacamay, W. Kline Bolton 
Volume 57, Issue 4, Pages (April 2000)
Activation of hepatocyte growth factor/activin A/follistatin system during hemodialysis: Role of heparin  Jacek Borawski, Beata Naumnik, Michał Myśliwiec 
Volume 61, Issue 6, Pages (June 2002)
Eric N Haugen, Anthony J Croatt, Karl A. Nath  Kidney International 
Volume 56, Issue 3, Pages (September 1999)
Effects of vitamin K antagonists (VKA), such as warfarin, low-molecular-weight heparin (LMWH), and dabigatran, on the coagulation pathway. Effects of vitamin.
Presentation transcript:

Volume 63, Issue 4, Pages 1548-1555 (April 2003) Depolymerized holothurian glycosaminoglycan (DHG), a novel alternative anticoagulant for hemodialysis, is safe and effective in a dog renal failure model  Kazuhisa Minamiguchi, Keiko T. Kitazato, Hideki Nagase, Eiji Sasaki, Katsuo Ohwada, Kenji Kitazato  Kidney International  Volume 63, Issue 4, Pages 1548-1555 (April 2003) DOI: 10.1046/j.1523-1755.2003.00879.x Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 1 Anticoagulant effects of depolymerized holothurian glycosaminoglycan (DHG), unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), and nafamostat mesilate (FUT) on clot deposition in drip chambers of the extracorporeal circuit. The amount of residual blood clot in each chamber is presented as hemoglobin content (see Methods section). Results indicate the mean ± SD (N = 5). *P < 0.05, **P < 0.01 vs. control by Wilcoxon's test. There is no difference among the glycosaminoglycans (GAGs). Kidney International 2003 63, 1548-1555DOI: (10.1046/j.1523-1755.2003.00879.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 2 Effects on activated partial thromboplastin time (APTT) (A) and thrombin clotting time (B) of depolymerized holothurian glycosaminoglycan (DHG), unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), and nafamostat mesilate (FUT). All samples were taken directly from the femoral artery except as indicated. Each point indicates the mean ± SD of five dogs. Normal APTT, 13.1 seconds; normal thrombin clotting time, 14.9 seconds. Symbols are: (○) saline control; (•) DHG, 5 mg/kg bolus + 2.5 mg/kg/hour drip infusion; (▵) UFH, 1 mg/kg bolus + 0.5 mg/kg/hour drip infusion; (□) LMWH, 3 mg/kg bolus + 1.5 mg/kg/hour drip infusion; (▸) FUT, 3 mg/kg/hour drip infusion; (▿) FUT, 3 mg/kg/hour drip infusion (sampled from extracorporeal circuit, inlet). Kidney International 2003 63, 1548-1555DOI: (10.1046/j.1523-1755.2003.00879.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 3 Effects on platelet count (A), white blood cell count (B), and hematocrit (C) of depolymerized holothurian glycosaminoglycan (DHG), unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), and nafamostat mesilate (FUT). Each point indicates the mean ± SD of five dogs. Symbols are: (○) saline control; (•) DHG, 5 mg/kg bolus + 2.5 mg/kg/hour drip infusion; (▵) UFH, 1 mg/kg bolus + 0.5 mg/kg/hour drip infusion; (□) LMWH, 3 mg/kg bolus + 1.5 mg/kg/hour drip infusion; (▾) FUT, 3 mg/kg/hour drip infusion. *P < 0.05, **P < 0.01 vs. control by Dunnet's test, and there is no difference among the glycosaminoglycans (GAGs). Kidney International 2003 63, 1548-1555DOI: (10.1046/j.1523-1755.2003.00879.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 4 Hemorrhagic effects of depolymerized holothurian glycosaminoglycan (DHG), unfractionated heparin (UFH), and low-molecular-weight heparin (LMWH). The template device was applied to the ear surface with care taken to avoid large veins, and blood from the wound was collected. Blood loss is expressed as hemoglobin content (see Methods section). Template bleeding was measured before surgery performed to induce renal failure (stage 1), prehemodialysis (HD-pre), and at 3 hours after the start of hemodialysis (HD-3 hr). Abbreviations are: D, DHG, 5 mg/kg bolus + 2.5 mg/kg/hour drip infusion; U, UFH, 1 mg/kg bolus + 0.5 mg/kg/hour drip infusion; L, LMWH, 3 mg/kg bolus + 1.5 mg/kg/hour drip infusion. Results indicate the mean ± SD (N = 5). *P < 0.05 vs. prehemodialysis values by paired t test. Kidney International 2003 63, 1548-1555DOI: (10.1046/j.1523-1755.2003.00879.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 5 Plasma concentrations of depolymerized holothurian glycosaminoglycan (DHG) (A), unfractionated heparin (UFH) (B), and low-molecular-weight heparin (LMWH) (C) during hemodialysis in dogs with renal failure. Each point indicates the mean ± SD (N = 5). Plasma concentrations of DHG, UFH, and LMWH were assayed by measuring antithrombin activity in the presence of bovine heparin cofactor II (see Methods section). Symbols are: (○) sampled directly from the femoral artery; (•) sampled from the extracorporeal circuit (ahead of the dialyzer); (▵) sampled from the extracorporeal circuit (beyond the dialyzer). Kidney International 2003 63, 1548-1555DOI: (10.1046/j.1523-1755.2003.00879.x) Copyright © 2003 International Society of Nephrology Terms and Conditions